Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs
Nucleic Acid Therapeutics · 01.04.2023 · 33 (2) · 83-94
DOI: 10.1089/nat.2022.0054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 30.03.2023. Verfasst von Hideo Takakusa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Oligonucleotides. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oligonucleotide therapeutics are attracting attention as a new treatment modality for a range of diseases that have been difficult to target using conventional approaches. Technical advances in chemical modification and drug delivery systems have led to the generation of compounds with excellent profiles as pharmaceuticals, and 16 oligonucleotide therapeutics have been marketed to date. There is a growing need to develop optimal and efficient approaches to evaluate drug metabolism and pharmacokinetics (DMPK) and drug–drug interactions (DDIs) of oligonucleotide therapeutics. The DMPK/DDI profiles of small molecule drugs are highly diverse depending on their structural and physicochemical characteristics, whereas oligonucleotide therapeutics share similar DMPK profiles within each chemistry type. Most importantly, the mechanisms and molecules involved in the distribution and metabolism of oligonucleotides differ from those of small molecules. In addition, there are considerations regarding experimental approaches in the evaluation of oligonucleotides, such as bioanalytical challenges, the use of radiolabeled tracers, materials for in vitro metabolism/DDI studies, and methods to study biodistribution. In this review, we attempt to summarize the DMPK characteristics of antisense oligonucleotide (ASO) therapeutics and discuss some of the issues regarding how to optimize the evaluation and prediction of the DMPK and DDI of ASOs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corp., Yokohama, Japan.
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.
- Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kawasaki, Japan.
- Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan.
ORCID-Profile: Makiya Nishikawa, Satoshi Obika
Zitieren
APA
Takakusa, H., Iwazaki, N., Nishikawa, M., Yoshida, T., Obika, S., & Inoue, T. (2023). Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Nucleic Acid Therapeutics, 33(2), 83-94. https://doi.org/10.1089/nat.2022.0054
Vancouver
Takakusa H, Iwazaki N, Nishikawa M, Yoshida T, Obika S, Inoue T. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Nucleic Acid Therapeutics. 2023;33(2):83-94. doi:10.1089/nat.2022.0054
BibTeX
@article{Takakusa2023,
author = {Takakusa, Hideo and Iwazaki, Norihiko and Nishikawa, Makiya and Yoshida, Tokuyuki and Obika, Satoshi and Inoue, Takao},
title = {Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs},
journal = {Nucleic Acid Therapeutics},
year = {2023},
volume = {33},
number = {2},
pages = {83--94},
doi = {10.1089/nat.2022.0054}
}
EUVIMED